This is a multicenter efficacy and tolerability study comparing Proscar (TM) and placebo in the treatment of symptomatic benign prostatic hyperplasia in a primary care setting. Efficacy will be evaluated by examining the following: 1) Symptomatic improvement, 2) improvement in QOL and ADL, and 3) Global Assessment of urologic status. Tolerability will be assessed by comparing clinical and lab adverse experience profiles.
Showing the most recent 10 out of 406 publications